Abstract
Estrogen/progestins replacement therapy prevents excess bone loss in post-menopausal women. The action of estrogen on bone is mainly through inhibiting bone resorption, but progestins exert its effect mainly through promoting bone formation. Recently osteoprotegerin (OPG) has been identified in osteoblast and displayed to inhibit bone resorption. The present study was performed to compare the action between E2 and P on OPG expression in cultured normal human osteoblast-like cells (hOB). OPG mRNA levels were determined by northern blot analysis, and OPG protein concentrations in conditioned media were determined by western immunoblot analysis and ELISA. After 24-48 h of treatment, E2 at 10−8M increased OPG mRNA levels and protein production in cultures of hOB, treatment with increasing dose of E2 caused a dose-dependent increase in the expression of OPG mRNA and protein by hOB. However, we also found out that after 12–48 h of treatment, progesterone at 10−8M had no effects on OPG mRNA levels and protein production in cultures of hOB, treatment with increasing dose of progesterone did not regulate the expression of OPG mRNA and protein by hOB. Thus, the data suggest that the different regulation of OPG production in osteoblasts by E2 and P may contribute to the mechanisms by which estrogen or progestins exerts its different action on bone resorption.
Similar content being viewed by others
References
Turner R.T., Riggs B.L., Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 1994, 16: 275–300.
MacNamara P., O’Shaughnessy C., Manduca P., Loughrey H.C. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif. Tissue Int. 1995, 57: 436–441.
Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95: 3597–602.
Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139: 1329–1337.
Tomoyasu A., Goto M., Fujise N., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 1998, 273: 5117–5123.
Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 1998, 247: 610–615.
Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 12608.
Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309–319.
Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelseberg T.C., Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprogerin in human osteoblastic cells. Endocrinology 1999, 140: 4367–4370.
Saika M., Inoue D., Kido S., Matsumoto T. 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 2001, 142: 2205–2212.
Eryuan L., Xianghang L. Effect of Effects of 17β-estradiol on the expression of matrix metalloproteinase-1, -2 and tissue inhibitor of metalloproteinase-1 in human osteoblastlike cells cultures. Endocrine 2001, 15: 11–16.
Vidal N.O.A., Brandstrom H., Jonsson K.B., Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J. Endocrinol. 1998, 159: 191–195.
Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, Bone morphogenetic protein, and cytokines. Biochem. Biophys. Res. Commun. 1998, 250: 776–781.
Jilka R.L. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998, 23: 75–81.
MacNamara P., O’Shaughnessy C., Manduca P., Loughrey H.C. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif. Tissue Int. 1995, 57: 436–441.
Rifas L., Kenney J.S., Marcelli M., et al. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor-α is not regulated by ovarin steroid. Endocrinology 1995, 136: 4056–4067.
Schmidt U.I., Wakley G.K., Turner R.T. Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif. Tissue Int. 2000, 67: 47–52.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liao, E.Y., Luo, X.H. & Su, X. Comparison of the effects of 17β-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 25, 785–790 (2002). https://doi.org/10.1007/BF03345513
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345513